The High Authority for Health (HAS) maintains its recommendation to restrict the use of AstraZeneca’s Covid-19 vaccine to people aged 55 and over. – Vincent Thian / AP / SIPA
Is there a link between the death of a 62-year-old woman, which occurred on Sunday, May 23 at the Toulouse University Hospital, and the AstraZeneca vaccine that it had been injected in early May. This is what the prosecution seeks to know which indicates to 20 minutes have opened an investigation “to search for the causes of death”, confirming information from La Dépêche du Midi.
The sexagenarian was from Vendée. She was on vacation in Revel, in the east of Haute-Garonne, for Pentecost when she was taken with a serious malaise, a priori cardiac, on Sunday. The emergency services were able to revive her and transport her to the CHU but her condition rapidly deteriorated until the fatal outcome. His family filed a complaint against X.
Thrombosis revealed by autopsy
From a source close to the investigation, the autopsy performed on May 25 revealed several thromboses. It will take further expertise to find out if this is a side effect of the serum. Toulouse departmental security investigators are continuing their investigations.
Since the start of the vaccination campaign, the National Medicines Safety Agency (ANSM) identified 45 cases of atypical thrombosis after AstraZeneca vaccinations, 8 of which resulted in the death of the patient. Among the fatal cases, there is that of the social worker who died at the Toulouse University Hospital on March 29. The complaint against X filed by his relatives is now being investigated at the Paris Health Center. Since March 19, the Haute Autorité de Santé has recommended reserving the AstraZeneca vaccine for people over 55 years of age.